Manufacturers, hospitals, physicians and patient advocates have put significant marketing resources—including millions of dollars—into selling 3D mammograms to women, despite little evidence the modality is better than traditional mammography.

“A better understanding of how age and comorbid conditions affect mammography use may help target specific populations and improve use of preventive care," wrote Cindy Yuan, MD, PhD, with the University of Chicago’s Department of Radiology, and colleagues.

The findings were true regardless of tumor type, size or cancer stage, wrote Pragya A. Dang, MD, and colleagues at Brigham and Women’s Hospital in Boston.

Men make up nearly 1% of all breast cancer cases in the U.S., but their mortality rate is drastically higher compared to women diagnosed with the disease.

More than 50% of the 43.7 million foreign-born people living in the U.S. are female—that figure is only expected to grow, explained lead author Tainya Clarke, PhD, MPH.

There is no shortage of research investigating the effectiveness of the Breast Imaging Reporting and Data System (BI-RADS) category 3 in mammography, but what’s less understood is why some women complete follow-up recommendations while many do not.

Breast cancer phenotype can influence MRI’s ability to evaluate the effectiveness of chemotherapy, according to a study published Oct. 4 in the European Journal of Radiology. But which specific tumor subtypes have the greatest impact on the modality’s performance?

The National Cancer Institute—part of the National Institutes of Health (NIH)—has awarded researchers at the University of Arizona Health Sciences $3.6 million to investigate a new imaging-based method to detect breast cancer.